OligometastasisNCT04085029
Role of Ablative Radiotherapy in the Management of Metastatic Disease: A Patient Data Registry
An observational study of Oligometastasis and Metastatic Cancer, run by Duke University at 5 sites in United States.
Trial summary
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Oligometastasis, Metastatic Cancer
- How many people
- 300 participants
- Where
- 5 sitesUnited States
- Study dates
- 26 Sep 2019to Sep 2029
- How long will I take part?
- 10 Years
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients at Duke University Health System Radiation Oncology treatment facilities or Durham VA Medical Center
Who may be able to join
- Age ≥ 18 years of age
- Radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment
- Planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s)
- Patient must sign study-specific informed consent
Who cannot join
- None
Trial locations and contacts
5 sites in 1 country. Contact the study team or a site near you to ask about taking part.
5 sites in 1 country
United States5 sites, 5 recruiting
- Recruiting
Duke Cancer Institute Cary
Cary, North Carolina, 27518
Clinical Trials Office, 919-668-3726, RadOnc-Clinical_Trials@dm.duke.edu
- Recruiting
Durham Veterans Administration Health Care System (DVAHCS)
Durham, North Carolina, 27705
Josephine Gaston, RN, josephine.gaston@va.gov
Joseph Salama, MD
- Recruiting
Duke University Medical Center
Durham, North Carolina, 27710
Clinical Trials Office, 919-668-3726, RadOnc-Clinical_Trials@dm.duke.edu
- Recruiting
Duke Women's Cancer Care Raleigh
Raleigh, North Carolina, 27607
Clinical Trials Office, 919-668-3726, RadOnc-Clinical_Trials@dm.duke.edu
- Recruiting
Duke Raleigh Hospital
Raleigh, North Carolina, 27609
Clinical Trials Office, 919-668-3726, RadOnc-Clinical_Trials@dm.duke.edu
About this study
The purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.
- Conditions
- Oligometastasis, Metastatic Cancer
- Keywords
- Ablative radiotherapy
- Medical subject headings
- Neoplasm Metastasis
What is being measured
The primary outcome is the main question the study is designed to answer.
Occurrence of acute adverse events following radiotherapy
Measured: 90 Days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Sep 2019
- Study start26 Sep 2019
- Primary completionSep 2029 (estimated)
- Study completionSep 2029 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for OligometastasisStudies of the same condition, open and under way.
- More trials run by Duke UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 300 participants (estimated)
- Target duration
- 10 Years
Sponsor and investigators
- Lead sponsor
- Duke University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
- Investigators
- Joseph Salama, MD, Principal investigator, Duke University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04085029
- Sponsor's protocol ID
- Pro00103137
- Status last verified
- Feb 2026
- First submitted
- 9 Sep 2019
- Last updated
- 5 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No